Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 5,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Completed Phase 1Phase 2 Interventional Results available

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

NCT01865617
View directory record Official record
Conditions
CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 22, 2026, 8:41 PM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 8:41 PM EDT
Completed Phase 2Phase 3 Interventional

Myfortic vs. Cellcept in Kidney Transplant Recipients

NCT00533624
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Mycophenolate Sodium Delayed Release Tablets, Mycophenolate Mofetil
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 22, 2026, 8:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

Comparing Adjuvant Treatments for High Tone Pelvic Floor Dysfunction

NCT07404397
View directory record Official record
Conditions
High Tone Pelvic Floor Dysfunction
Interventions
Cyclobenzaprine, Pelvic floor massage wand, Pelvic floor physical therapy
Drug · Device · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 22, 2026, 8:41 PM EDT
Recruiting Phase 1 Interventional

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT05187182
View directory record Official record
Conditions
Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
Interventions
CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Working Memory Training Combined With Transcranial Magnetic Stimulation in Smokers

NCT03337113
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Working Memory Training, Sham Working Memory Training, repetitive Transcranial Magnetic Stimulation, Sham repetitive Transcranial Magnetic Stimulation
Other · Device
Lead sponsor
Kent State University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 22, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions
Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
36
States / cities
Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 22, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Veterans Affairs Lowering Readmission in Heart Failure

NCT01144182
View directory record Official record
Conditions
Heart Failure
Interventions
Comprehensive quality improvement program (QIP)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 22, 2026, 8:41 PM EDT
Recruiting Not applicable Interventional

MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors

NCT05373823
View directory record Official record
Conditions
Melanoma
Interventions
MySmartSkin enhancement, Educational webpage on Skin Self-Examination, Assess implementation outcomes
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 8:41 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Hepatitis C Positive Donor Into Hepatitis C Negative Recipients

NCT03702218
View directory record Official record
Conditions
Hepatitis C
Interventions
Direct Acting Antivirals
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 22, 2026, 8:41 PM EDT
Enrolling by invitation Not applicable Interventional

Neuromodulation of Spinal Locomotor Circuitry to Elicit Stepping After Pediatric Spinal Cord Injury

NCT04077346
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Biostim-5 transcutaneous spinal stimulator, Transcutaneous Spinal Stimulator + Activity Based Locomotor Training
Device · Other
Lead sponsor
University of Louisville
Other
Eligibility
4 Years to 12 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Evaluation of an Acceptance and Commitment Therapy-Based Narrative Intervention for Individuals Taking Antidepressants

NCT04757961
View directory record Official record
Conditions
Depressive Symptoms
Interventions
LifeStories
Behavioral
Lead sponsor
Utah State University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 22, 2026, 8:41 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Comparing Two Treatments That Both Target Smoking Cessation and Weight Loss at the Same Time.

NCT04130698
View directory record Official record
Conditions
Smoking Cessation, Weight Loss
Interventions
Distress Tolerance, transdermal nicotine patch, Active Health Control
Behavioral · Drug
Lead sponsor
Rhode Island College
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 22, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

NCT05001516
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
LM-302
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Fullerton, California • Lafayette, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 22, 2026, 8:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Text Messaging to Improve Adherence to Web-Based Cessation Treatment

NCT02585206
View directory record Official record
Conditions
Smoking Cessation
Interventions
Personalization, Integration, Dynamic Tailoring, Message Intensity, Optimal-Adherence Text
Behavioral
Lead sponsor
Truth Initiative
Other
Eligibility
18 Years and older
Enrollment
1,485 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 8:41 PM EDT
Terminated Phase 1 Interventional

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

NCT00734526
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide, Radiation, Sorafenib
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 22, 2026, 8:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

NCT06100276
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMT-162
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 22, 2026, 8:41 PM EDT
Active, not recruiting Not applicable Interventional

Telehealth Stepped Exercise Program for Rural Veterans With Knee Osteoarthritis

NCT04775589
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Stepped Exercise for Knee Osteoarthritis
Behavioral
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 22, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

NCT05883449
View directory record Official record
Conditions
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Interventions
AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
Drug
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 22, 2026, 8:41 PM EDT
Active, not recruiting Phase 4 Interventional

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

NCT06433635
View directory record Official record
Conditions
Bipolar I Disorder, Depression
Interventions
Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
2,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 22, 2026, 8:41 PM EDT
Completed No phase listed Observational

Digital Tools for Assessment of Motor Functions and Falls in ALS

NCT05271435
View directory record Official record
Conditions
ALS, PLS, PMA
Interventions
PAMSys Activity Monitoring System, Motor, Speech, and Handwriting Assessment
Device · Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Improving Access to Community-Based Occupations Via a Rideshare Training Program

NCT06323850
View directory record Official record
Conditions
Autism
Interventions
Intervention Phase, Virtual Training Sessions, Ride-Along Training Sessions
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 22, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

NCT02646748
View directory record Official record
Conditions
Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer, Lung Cancer, MMR-deficient Tumors, Breast Cancer, Pancreatic Cancer, Renal Cell Carcinoma (RCC), Solid Tumors, UC (Urothelial Cancer)
Interventions
Pembrolizumab, itacitinib, INCB050465
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 22, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Shockwave, Photobiomodulation, and Physical Therapy for Achilles Tendinopathy

NCT05751785
View directory record Official record
Conditions
Achilles Tendinopathy
Interventions
Physical Therapy, Shockwave Therapy, Photobiomodulation Therapy
Other · Device
Lead sponsor
Musculoskeletal Injury Rehabilitation Research for Operational Readiness
Federal
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 22, 2026, 8:41 PM EDT